Press and Announcements

Please check back frequently for news, announcements, and events.

 

Homepage-Pipeline

ipeline Praetego’s novel small molecules (Amadorins) are derived from a clinically proven prototype. Our primary indication is Diabetic Peripheral Neuropathy (DPN), a condition plaguing about 50% of diabetics. The Amadorins are designed to limit disease progression. Read More >